3/23
08:00 am
btai
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
Medium
Report
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
3/17
08:25 am
btai
BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
3/12
02:35 pm
btai
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
Low
Report
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
3/11
04:38 pm
btai
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]
3/11
04:20 pm
btai
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Low
Report
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
3/11
07:18 am
btai
BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".
3/10
02:36 pm
btai
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
Low
Report
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
3/5
11:44 am
btai
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
3/5
07:41 am
btai
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal [Yahoo! Finance]
High
Report
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal [Yahoo! Finance]
3/5
07:00 am
btai
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
High
Report
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
2/27
06:12 pm
btai
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript [Seeking Alpha]
Low
Report
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript [Seeking Alpha]
2/19
07:34 am
btai
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia [Yahoo! Finance]
2/19
07:00 am
btai
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Low
Report
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
2/12
07:00 am
btai
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
Medium
Report
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
1/30
07:57 am
btai
BioXcel Therapeutics (NASDAQ:BTAI) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
BioXcel Therapeutics (NASDAQ:BTAI) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/20
07:00 am
btai
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
Low
Report
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
1/15
12:44 pm
btai
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
1/12
08:55 am
btai
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting [Yahoo! Finance]
1/12
07:00 am
btai
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
Low
Report
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
1/7
07:13 am
btai
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® [Yahoo! Finance]
High
Report
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® [Yahoo! Finance]
1/7
07:00 am
btai
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
High
Report
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®